Abstract:Pinyi Zhang, 1 Jianlong Bu, 2 Xiaohong Wu, 1 Lin Deng, 1 Meng Chi, 1 Chao Ma, 3 Xiaoding Shi, 1 Guonian Wang 3 1 Department of Anesthesiology, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China; 2 Department of Thoracic Surgery, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China; 3 Department of Anesthesiology, The Fourth Hospital of Harbin Medical University, Harbin, People's Republic of China Correspondence: Guonian Wang Department of Anesthesiology, The Fourth Hospital of Harbin Medical University, Nangang District, Harbin 150081, People's Republic of China Tel +86 15804616023 Email wangguonian609cn@aliyun.com Background: Sustained morphine treatment for cancer pain has been limited due to analgesic tolerance. Opioid receptor internalization and desensitization mediated by downregulation of mu-opioid receptor (MOR) expression have been confirmed as one of the mechanisms of chronic morphine tolerance. In addition to the opiate system, the α 2-adrenergic system is involved in the development of morphine tolerance. Several studies reported that co-administration of α 2-adrenoceptor agonist dexmedetomidine inhibits morphine tolerance in normal or neuropathic pain animals. However, the effect of dexmedetomidine on morphine tolerance has not been studied in cancer pain. Therefore, we investigated the effect of intrathecal injection of dexmedetomidine on the development of morphine tolerance in cancer pain and on the expression of MOR in the spinal cord of morphine-tolerant cancer pain rats. Methods: The model was established using a rat's right hind paw injection of Walker 256 cancer cells. Subcutaneous morphine (10mg/kg) was administrated twice daily for 7 days; meanwhile, the rats received intrathecal α 2-adrenoceptor agonist dexmedetomidine (10μ/kg) or antagonist MK-467 (0.25mg/kg) in test groups. Rats receiving drug vehicle served as the control group. Antinociception was detected by von Frey filaments and hot-plate tests. The expression of MOR in the spinal cord was examined through real-time reverse transcription polymerase chain reaction and Western blotting. The data were analyzed via analysis of variance followed by Student t -test with Bonferroni correction. Results: Seven-day chronic morphine administration elicited notable analgesic tolerance in the rats with cancer pain. Co-administration of α 2-adrenoceptor agonist dexmedetomidine enhanced morphine analgesia and attenuated morphine tolerance, which could be blocked by α 2-adrenoceptor antagonist MK-467. Furthermore, pre-treatment of dexmedetomidine significantly upregulated MOR protein expression without a notable change in MOR mRNA expression in the spinal cord. Conclusion: Our findings suggest that intrathecal injection of dexmedetomidine enhanced morphine analgesia and attenuated morphine tolerance in cancer pain, potentially by upregulating MOR expression in the spinal cord. The α 2-adrenoceptor agonist may provide a more versatile analgesia option for morphine treatment for cancer pain. Keywords: μ-opioid receptor, MOR, α 2-adrenoceptor, α 2-AR, dexmedetomidine, DEX, morphine tolerance, cancer pain

Synergistic Interaction Between Butorphanol and Dexmedetomidine in Antinociception

Additive analgesic effect of dexmedetomidine and dezocine administered intrathecally in a mouse pain model

Morphine and clonidine combination therapy improves therapeutic window in mice: synergy in antinociceptive but not in sedative or cardiovascular effects

Antinociceptive Interactions between the Imidazoline I2 Receptor Agonist 2-BFI and Opioids in Rats: Role of Efficacy at the μ-Opioid Receptor.

Antinociceptive synergy in a peripheral hyperalgesia model: interplay of cannabinoidergic, adrenergic, and opioidergic systems and their antagonism

The Effects of Morphine, Baclofen, and Buspirone Alone and in Combination on Schedule-Controlled Responding and Hot Plate Antinociception in Rats

Synergistic Interaction Between DAMGO-NH2 and NOP01 in Peripherally Acting Antinociception in Two Mouse Models of Formalin Pain

Effect of butorphanol tartrate combined with dexmedetomidine on postoperative analgesia

Application of Receptor Theory to the Design and Use of Fixed-Proportion Mu-Opioid Agonist and Antagonist Mixtures in Rhesus Monkeys

Assessing the synergistic effects of morphine and MP‐III‐024 co‐administration: enhanced antinociception with reduced side effects

Effect of Butorphanol Combined with Dexmedetomidine on Postoperative Hyperalgesia Induced by Remifentanil

Dexmedetomidine, an α2 agonist, increases the morphine analgesic effect and decreases morphine tolerance development by suppressing oxidative stress and TNF/IL-1 signalling pathway in rats

Upregulation of μ-Opioid Receptor in the Rat Spinal Cord Contributes to the α2-Adrenoceptor Agonist Dexmedetomidine-Induced Attenuation of Chronic Morphine Tolerance in Cancer Pain

Tramadol and Dihydroetorphine Produce Synergistic Analgesic Effect and Postpones Acute Opiate Tolerance in Rats

Role of Mu-Opioid Agonist Efficacy on Antinociceptive Interactions Between Mu Agonists and the Nociceptin Opioid Peptide Agonist Ro 64-6198 in Rhesus Monkeys.

Synaptic Mechanism for Functional Synergism Between Δ- and Μ-Opioid Receptors

Dexmedetomidine Infusion for the Management of Opioid-Induced Hyperalgesia

Dexmedetomidine Prevents Remifentanil-Induced Postoperative Hyperalgesia and Decreases Spinal Tyrosine Phosphorylation of N-methyl-d-aspartate Receptor 2B Subunit.

Interactions of the potent D-amino acid oxidase inhibitor CBIO with morphine in pain and tolerance to analgesia.

Peripheral interactions between cannabinoid and opioid receptor agonists in a model of inflammatory mechanical hyperalgesia

Pre‐emptive Analgesia and Its Supraspinal Mechanisms: Enhanced Descending Inhibition and Decreased Descending Facilitation by Dexmedetomidine